Full Name
Dr. Giada Sebastiani
Speaker Bio
Dr. Giada Sebastiani is Professor of Medicine at McGill University and Clinician-Scientist at the Research Institute of the McGill University Health Centre in Montreal, Canada. She is currently President of the Canadian Association for the Study of the Liver and recipient of the prestigious Chercheuse de mérite salary award from the Fonds de recherche du Québec – Santé (FRQS).
Dr. Sebastiani obtained her medical degree and specialized in Internal Medicine at the University of Padua, Italy. She subsequently undertook clinical and basic research training at Harvard Medical School (USA), University College London (UK), the University of Bordeaux (France), and the Lady Davis Institute for Medical Research (Canada).
Her research focuses on MASLD, liver fibrosis, non-invasive diagnostic tools, and innovative models of care, with particular emphasis on early detection and equitable screening in at-risk populations, including people living with HIV, individuals with type 2 diabetes or obesity, patients with inflammatory bowel disease, and women.
Dr. Sebastiani has authored 260 peer-reviewed publications, with over 17,500 citations and an h-index of 58. She has been recognized among the world's top 2% of scientists, based on the composite citation index (c-index) in a bibliometric assessment encompassing nearly seven million researchers across all scientific disciplines.
She is a co-founder and Steering Committee member of the Canadian MASLD Network (CanMASLD), Co-Chair of the first MASLD chapter of the Diabetes Canada Clinical Practice Guidelines, and contributor to several national and international clinical practice guidelines and consensus statements.
An internationally recognized speaker, Dr. Sebastiani was elected Fellow of the American Association for the Study of Liver Diseases in 2024 and received the 2026 McGill Department of Medicine Mid-Career Research Award. Her research program is funded by CIHR, FRQS and Crohn's Colitis Canada.
Dr. Sebastiani obtained her medical degree and specialized in Internal Medicine at the University of Padua, Italy. She subsequently undertook clinical and basic research training at Harvard Medical School (USA), University College London (UK), the University of Bordeaux (France), and the Lady Davis Institute for Medical Research (Canada).
Her research focuses on MASLD, liver fibrosis, non-invasive diagnostic tools, and innovative models of care, with particular emphasis on early detection and equitable screening in at-risk populations, including people living with HIV, individuals with type 2 diabetes or obesity, patients with inflammatory bowel disease, and women.
Dr. Sebastiani has authored 260 peer-reviewed publications, with over 17,500 citations and an h-index of 58. She has been recognized among the world's top 2% of scientists, based on the composite citation index (c-index) in a bibliometric assessment encompassing nearly seven million researchers across all scientific disciplines.
She is a co-founder and Steering Committee member of the Canadian MASLD Network (CanMASLD), Co-Chair of the first MASLD chapter of the Diabetes Canada Clinical Practice Guidelines, and contributor to several national and international clinical practice guidelines and consensus statements.
An internationally recognized speaker, Dr. Sebastiani was elected Fellow of the American Association for the Study of Liver Diseases in 2024 and received the 2026 McGill Department of Medicine Mid-Career Research Award. Her research program is funded by CIHR, FRQS and Crohn's Colitis Canada.
